Naesens Maarten, Lerut Evelyne, Emonds Marie-Paule, Herelixka Albert, Evenepoel Pieter, Claes Kathleen, Bammens Bert, Sprangers Ben, Meijers Björn, Jochmans Ina, Monbaliu Diethard, Pirenne Jacques, Kuypers Dirk R J
Department of Microbiology and Immunology, KU Leuven - University of Leuven, and Department of Nephrology, University Hospitals Leuven, Leuven, Belgium;
Department of Imaging and Pathology, KU Leuven - University of Leuven, and Department of Pathology, University Hospitals Leuven, Leuven, Belgium;
J Am Soc Nephrol. 2016 Jan;27(1):281-92. doi: 10.1681/ASN.2015010062. Epub 2015 Jul 7.
Proteinuria is routinely measured to assess renal allograft status, but the diagnostic and prognostic values of this measurement for renal transplant pathology and outcome remain unclear. We included 1518 renal allograft recipients in this prospective, observational cohort study. All renal allograft biopsy samples with concomitant data on 24-hour proteinuria were included in the analyses (n=2274). Patients were followed for ≥7 years post-transplantation. Compared with proteinuria <0.3 g/24 h, the hazard ratios for graft failure were 1.14 (95% confidence interval [95% CI], 0.81 to 1.60; P=0.50), for proteinuria 0.3-1.0 g/24 h, 2.17 (95% CI, 1.49 to 3.18; P<0.001), for proteinuria 1.0-3.0 g/24 h, and 3.01 (95% CI, 1.75 to 5.18; P<0.001), for proteinuria >3.0 g/24 h, independent of GFR and allograft histology. The predictive performance of proteinuria for graft failure was lower at 3 months after transplant (area under the receiver-operating characteristic curve [AUC] 0.64, P<0.001) than at 1, 2, and 5 years after transplant (AUC 0.73, 0.71, and 0.77, respectively, all P<0.001). Independent determinants of proteinuria were repeat transplantation, mean arterial pressure, transplant glomerulopathy, microcirculation inflammation, and de novo/recurrent glomerular disease. The discriminatory power of proteinuria for these intragraft injury processes was better in biopsy samples obtained >3 months after transplant (AUC 0.73, P<0.001) than in those obtained earlier (AUC 0.56, P<0.01), with 85% specificity but lower sensitivity (47.8%) for proteinuria >1.0 g/24 h. These data support current clinical guidelines to routinely measure proteinuria after transplant, but illustrate the need for more sensitive biomarkers of allograft injury and prognosis.
蛋白尿通常用于评估肾移植受者的移植肾状态,但该指标对肾移植病理及预后的诊断和预测价值仍不明确。在这项前瞻性观察队列研究中,我们纳入了1518例肾移植受者。分析中纳入了所有伴有24小时蛋白尿数据的肾移植活检样本(n = 2274)。对患者进行了≥7年的移植后随访。与蛋白尿<0.3 g/24小时相比,移植肾失功的风险比在蛋白尿为0.3 - 1.0 g/24小时时为2.17(95%置信区间[95%CI],1.49至3.18;P<0.001),在蛋白尿为1.0 - 3.0 g/24小时时为3.01(95%CI,1.75至5.18;P<0.001),在蛋白尿>3.0 g/24小时时为3.01(95%CI,1.75至5.18;P<0.001),且独立于肾小球滤过率和移植肾组织学。移植后3个月时,蛋白尿对移植肾失功的预测性能(受试者工作特征曲线下面积[AUC]为0.64,P<0.001)低于移植后1年、2年和5年(AUC分别为0.73、0.71和0.77,均P<0.001)。蛋白尿的独立决定因素包括再次移植、平均动脉压、移植性肾小球病、微循环炎症以及新发/复发性肾小球疾病。对于这些移植肾内损伤过程,蛋白尿在移植后>3个月获取的活检样本中的鉴别能力(AUC为0.73,P<0.001)优于早期获取的样本(AUC为0.56,P<0.01),对于蛋白尿>1.0 g/24小时,特异性为85%,但敏感性较低(47.8%)。这些数据支持目前移植后常规检测蛋白尿的临床指南,但也表明需要更敏感的移植肾损伤和预后生物标志物。